Myriad Genetics (MYGN) Short-term Investments (2010 - 2024)

Myriad Genetics has disclosed Short-term Investments across 15 years of filings, most recently posting $4.9 million for Q2 2024.

• In Q2 2024, Short-term Investments fell 73.94% year-over-year to $4.9 million; the TTM figure through Jun 2024 stood at $4.9 million (down 73.94% YoY), while the FY2023 annual figure was $8.8 million, down 84.83% from the prior year.
• Short-term Investments eased to $4.9 million in Q2 2024, from $7.4 million in the prior quarter.
• Over the last five years, Short-term Investments for MYGN reached as high as $103.2 million in Q1 2022 and fell as low as $4.9 million in Q2 2024.
• The 5-year median for Short-term Investments is $44.0 million (2020), against an average of $46.4 million.
• Annual changes were most pronounced in 2022 — Short-term Investments surged 279.41% — and 2023, when it slumped 87.52%.
• A 5-year view of Short-term Investments shows it stood at $33.7 million in 2020, then soared by 141.54% to $81.4 million in 2021, then decreased by 28.75% to $58.0 million in 2022, then tumbled by 84.83% to $8.8 million in 2023, then slumped by 44.32% to $4.9 million in 2024.
• According to Business Quant data, Short-term Investments over the past three periods registered $4.9 million, $7.4 million, and $8.8 million for Q2 2024, Q1 2024, and Q4 2023 respectively.